Elanco Q1 revenue +15% to $1.37B, raises FY2026 guidance across all metrics

Elanco Animal Health Inc

2026-Q1 EPS reported $0.11 revenue$1,371,000,000

Q1 revenue $1.37B (+15% reported, +10% organic constant currency); adjusted EPS $0.40 vs $0.37 prior year.
Full-year 2026 guidance raised: revenue $5,010-$5,085M, adj. EBITDA $975-$1,005M, adj. EPS $1.03-$1.09.
Q2 2026 guidance: revenue $1,300-$1,325M, adj. EBITDA $240-$260M, adj. EPS $0.25-$0.28.
Innovation revenue target raised to $1.2B; net leverage target improved to 3.0x-3.2x.
Credelio Quattro and Zenrelia post strong share gains; closed AHV International acquisition Apr 30.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.